Trade this ETF at your broker
Index | Nasdaq Biotechnology |
Investment focus | Equity, United States, Health Care |
Fund size | EUR 33 m |
Total expense ratio | 0.35% p.a. |
Replication | Physical (Optimized sampling) |
Legal structure | ETF |
Strategy risk | Long-only |
Sustainability | No |
Fund currency | USD |
Currency risk | Currency unhedged |
Volatility 1 year (in EUR) | 17.83% |
Inception/ Listing Date | 5 March 2018 |
Distribution policy | Distributing |
Distribution frequency | Semi annually |
Fund domicile | Ireland |
Fund Provider | iShares |
Fund Structure | Open-ended Investment Company (OEIC) |
UCITS compliance | Yes |
Administrator | State Street Fund Services (Ireland) Limited |
Investment Advisor | |
Custodian Bank | State Street Custodial Services (Ireland) Limited |
Revision Company | Deloitte |
Fiscal Year End | 31 May |
Swiss representative | BlackRock Asset Management Schweiz AG |
Swiss paying agent | State Street Bank International GmbH, Munich, Zurich Branch |
Tax data | Bundesanzeiger | |
Germany | 30% tax rebate | |
Switzerland | ESTV Reporting | |
Austria | Tax Reporting Fund | |
UK | UK Reporting |
Indextype | Total return index |
Swap counterparty | - |
Collateral manager | Bank of New York Mellon|Euroclear|JP Morgan|State Street Bank |
Securities lending | Yes |
Securities lending counterparty | Barclays Bank Plc|Barclays Capital Securities Ltd.|BNP Paribas Arbitrage SNC|BNP Paribas SA|Citigroup Global Markets Ltd|Citigroup Inc|Credit Suisse Securities (Europe) Ltd.|Deutsche Bank AG|Goldman Sachs International|HSBC Bank Plc|J.P. Morgan Securities Plc|JP Morgan Chase & Co|Macquarie Bank Limited|Merrill Lynch International|Morgan Stanley & Co. International Plc|Nomura International Plc|Skandinaviska Enskilda Banken AB|Societe Generale SA|The Bank of Nova Scotia|UBS AG |
Vertex Pharmaceuticals | 8.73% |
Regeneron Pharmaceuticals | 8.63% |
Amgen | 7.47% |
Gilead Sciences | 6.93% |
AstraZeneca PLC ADR | 3.65% |
Moderna | 3.60% |
Biogen | 3.22% |
Illumina | 2.27% |
Alnylam Pharmaceuticals | 1.94% |
BioMarin Pharmaceutical | 1.67% |
United States | 83.31% |
Ireland | 1.42% |
Bermuda | 1.02% |
Other | 14.25% |
Health Care | 88.80% |
Other | 11.20% |
YTD | -1.92% |
1 month | -4.25% |
3 months | -3.60% |
6 months | +8.67% |
1 year | +0.76% |
3 years | -2.97% |
5 years | +33.21% |
Since inception (MAX) | +38.47% |
2023 | +0.76% |
2022 | -5.13% |
2021 | +8.09% |
2020 | +15.15% |
Current dividend yield | 0.41% |
Dividends (last 12 months) | EUR 0.02 |
Period | Dividend in EUR | Dividend yield in % |
---|---|---|
1 Year | EUR 0.02 | 0.41% |
2023 | EUR 0.02 | 0.40% |
2022 | EUR 0.03 | 0.42% |
2021 | EUR 0.01 | 0.26% |
2020 | EUR 0.01 | 0.21% |
Volatility 1 year | 17.83% |
Volatility 3 years | 23.24% |
Volatility 5 years | 25.53% |
Return per risk 1 year | 0.04 |
Return per risk 3 years | -0.04 |
Return per risk 5 years | 0.23 |
Maximum drawdown 1 year | -11.97% |
Maximum drawdown 3 years | -31.04% |
Maximum drawdown 5 years | -31.04% |
Maximum drawdown since inception | -31.04% |
Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
---|---|---|---|---|---|
gettex | EUR | OM3E | - - | - - | - |
London Stock Exchange | USD | BTEE | BTEE LN INAVBTDU | BTTE.L |
Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
---|---|---|---|---|
iShares Nasdaq US Biotechnology UCITS ETF | 416 | 0.35% p.a. | Accumulating | Sampling |
Invesco Nasdaq Biotech UCITS ETF | 307 | 0.40% p.a. | Accumulating | Swap-based |